Researchers have identified prognostic factors associated with cardiovascular (CV) and non-CV mortality in elderly patients with chronic heart failure (CHF), and are calling for preventive measures to begin as early as the age of 65 years in patients with CHF.
Most patients on the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan are started on the lowest dose and remain on the lowest or intermediate dose of the drug, data from primary care and cardiology practices in Germany have shown.
Cost, concerns over a lack of long-term clinical data, and injection fear were the top reasons cited for nonadherence to evolocumab therapy, according to a small study assessing the real-world barriers among patients with coronary artery disease (CAD).
Although higher levels of HDL-cholesterol (HDL-C) are associated with reduced cardiovascular disease (CVD) risk, the relationship is not linear and after an intermediate range of 50–70 mg/dL, very high HDL-C is not always associated with lower CV risk.
In patients with heart failure with reduced ejection fraction (HFrEF), switch of therapy from an angiotensin-converting enzyme inhibitor (ACEI) to the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan significantly improves left ventricular ejection fraction (LVEF) at 1 year.
A meta-analysis of 1,526 patients showed that proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are safe and effective compared with placebo at reducing LDL-cholesterol (LDL-C) in patients with familial hypercholesterolaemia (FH).
A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.